Latest "Standard & Poor’s" News Stories - Page: 2

08:37 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "Standard & Poor’s" found in our extensive news archives from over 250 global news sources.

More Information about Standard & Poor’s on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Standard & Poor’s for you to read. Along with our medical data and news we also list Standard & Poor’s Clinical Trials, which are updated daily. BioPortfolio also has a large database of Standard & Poor’s Companies for you to search.

Showing "Standard Poor" News Articles 26–50 of 3,500+

Wednesday 12th December 2018

Luye Pharma's Global Strategy For CNS-Focused Products Gathers Pace: Rotigotine Extended Release Microspheres Submitted to Japan's PMDA for Clinical Trial Approval

SHANGHAI, Dec. 12, 2018 /PRNewswire/ -- Luye Pharma announced that its new investigational drug, Rotigotine Extended Release Microspheres for Injection (LY03003) for the treatment of Parkinson's disease has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for clinical trial approval. Meanwhile Phase III clinical trials for LY03003 in the U.S. and China are progressi...

MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study results 12.12.2018 / 13:36 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, December 12, 2018   MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment ...

Vocera Improves Clinical Workflows at a North Carolina Hospital

Technology helps enhance surveillance monitoring and patient experience Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Wake Forest Baptist Health deployed Vocera technology at a second hospital, Wake Forest Baptist Health Davie Medical Center, to improve clinical ...

Young Breast Cancer Patients Face Higher Risk for Osteoporosis

WEDNESDAY, Dec. 12, 2018 -- The risk for bone loss rises sharply in young breast cancer patients who received standard treatment, according to a study recently published in Breast Cancer Research. Cody Ramin, Ph.D., from Johns Hopkins University in...

CO.DON AG: Delivery of machinery to Leipzig site complete

DGAP-News: CO.DON AG / Key word(s): Expansion 12.12.2018 / 11:00 The issuer is solely responsible for the content of this announcement. CO.DON AG - Delivery of machinery to Leipzig site complete Berlin / Teltow, 12.12.2018 - Only 11 months after the contract was signed, the clean room technology for the new production site has all been delivered. The components were transported from B...

Mississauga’s St. Lawrence Dentistry Offers Sedation Dental Services To Ease Patient Discomfort And Anxiety

St. Lawrence Dentistry offers affordable and safe sedation dentistry options for children and adults, providing a pain-free alternative for those who might experience fear or anxiety during dental procedures. TORONTO (PRWEB) December 12, 2018 St. Lawrence Dentistry offers several dental services in Mississauga, and is licensed by the Royal College of Dental Surgeons of Ontario to provide sedation...

InterVenn BioSciences Raises $9.4 Million to Help Physicians Detect Early Ovarian Cancer With a Minimally Invasive Test

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression. InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional investmen...

Juniper Research: Hearables to Revolutionise Personal Audio With Over 50% of all Wireless Headphones Incorporating Hearable Tech by 2022

Voice assistants, touch sensors and other interface technologies will become the new standard for personal audio in under 5 years. A new report from Juniper Research has found that there will be an estimated 417 million hearables in use by 2022. This includes fitness-focused devices, hearing augmentation and purely audio-focused devices. ...

Avacta appoints Dr Jose Saro as Chief Medical Officer

Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s ...

Tuesday 11th December 2018

Delayed cord clamping in preterm infants: is it time to become standard practice?

Aravive begins Phase Ib part of ovarian cancer drug trial

Aravive has commenced the Phase Ib portion of a clinical trial evaluating the combination of AVB-S6-500 with standard-of-care to treat...Read More... The post Aravive begins Phase Ib part of ovarian cancer drug trial appeared first on Drug Development Technology.

College textbooks largely overlook the most common animals

(North Carolina State University) A recent study of textbooks aimed at introductory biology courses finds that they devote less than one percent of their text to discussing insects, which make up more than 60 percent of animal species. The study authors argue that this provides a poor foundation for understanding ecosystems, biodiversity, and other core aspects of biological research.

Standard Life UK Smaller Companies (SLS) - Disciplined approach driving outperformance

Edison Investment Research - Investment Companies - Standard Life UK Smaller Companies: Standard Life UK Smaller Companies (SLS) is managed by Harry Nimmo at Aberdeen Standard Investments. He has followed the same investment process since he took over management of the trust in 2003, through a number of economic cycles, and considers it to be stable, predictable and well defined, while providing a...

PACIFIC Trial Changes Standard of Care in Stage III NSCLC

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

Aravive (Nasdaq:ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer. As quoted in the press release: “We are excited to have begun enrollment in this clinical trial …...

Global Thrombosis Drugs Market 2019-2023 | Introduction of Novel Oral Anticoagulants Drives Growth | Technavio

Technavio’s global thrombosis drugs market research report forecasts the market to grow at a CAGR of more than 9% during the forecast period. This press release features multimedia. View the full release here:

Microplate design enhances fluorescence and luminescence measurement

Porvair Sciences' unique Krystal 2000 microplate range sets a new standard for luminescence and fluorescence assays

High Cost of Insulin Is Associated with Underuse and Poor Glycemic Control

A quarter of patients reported cost-related insulin underuse.

Seeta Eye Centers Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

Satish Modi, M.D. at Seeta Eye Centers in Poughkeepsie, NY, is participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts. By the age of 65, an estimated 90% of people worldwide experience changes to the natural crystalline lens of the eye. The lens gradually becomes cloudy as a cat...

Dilute-N-Go® Syringes Now Available from Pentec Health’s 503B Outsourcing Facility

Dilute-N-Go® Syringes Now Available from Pentec Health’s 503B Outsourcing Facility, Continuing to Help Fill the Gap of Critically Needed IV Medications GLEN MILLS, Pa. (PRWEB) December 11, 2018 Pentec Health, Inc., an established leader in sterile compounding, announced the launch of their single-use Dilute-N-Go® syringe based products from their 503B Outsourcing Facility. These paten...

National Institute for Health and Care Excellence (NICE) Issues New Guidelines for COPD, Recommending Severe Patients be Evaluated for Bronchoscopic Lung Volume Reduction

NICE makes a “strong” recommendation that patients with severe COPD be referred for evaluation for bronchoscopic lung volume reduction, including the Zephyr® Endobronchial Valve System. NICE has broadened the criteria for evaluation and a new group of people for whom lung volume reduction surgery was unsuitable may now ...

Versant Ventures Launches Black Diamond Therapeutics

Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company ...

Standard Missile-3 Block IIA destroys target in first intercept from land

PACIFIC MISSILE RANGE FACILITY, Hawaii, Dec. 11, 2018 /PRNewswire/ -- The Missile Defense Agency completed the third successful intercept of a ballistic missile target by Read more...

AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition

Clinical professionals can now utilize a 6-minute MRI scan to access best-in-class measurements of body fat and muscle, alongside high-quality medical images, to assist in patient diagnosis AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now...

Simple Safe Parallel Reaction Sampling

Asynt has introduced the DrySyn OCTO Mini Conversion Kit to enable chemists to efficiently sample reactions performed using their DrySyn OCTO 8-position parallel synthesiser. The DrySyn OCTO is a compact, entry-level parallel synthesiser for chemists wishing to conduct synthetic reactions under an inert atmosphere with temperature control and powerful magnetic st...

Quick Search


News Quicklinks